A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
This is prospective, randomized, open-label, multicenter, phase 2 study of gemcitabine with
or without bavituximab in patients with previously untreated stage IV pancreatic cancer.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
To compare the overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
United States: Food and Drug Administration
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Dartmouth-Hitchcock Medical Center||Lebanon, New Hampshire 03756|
|Moores UCSD Cancer Center||La Jolla, California 92093-0658|
|Northeast Georgia Medical Center||Gainesville, Georgia 30501|
|John B. Amos Cancer Center||Columbus, Georgia 31904|
|Lynchburg Hematology-Oncology Clinic||Lynchburg, Virginia 24501|
|Joliet Oncology-Hematology Associates, Ltd.||Flossmoor, Illinois 60422|
|Arena Oncology Associates, PC||Great Neck, New York 11021|
|St. Luke's Cancer Center||Bethlehem, Pennsylvania 18015|
|Lynn Cancer Institute||Boca Raton, Florida 33428|
|Ironwood Cancer & Research Centers||Chandler, Arizona 85224|
|The Cancer Center at DeKalb Medical||Decatur, Georgia 30033|
|Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler||Savannah, Georgia 31405|
|Leo W. Jenkins Cancer Center - East Carolina University||Greenville, North Carolina 27834|
|Vasicek Cancer Center at Scott & White Memorial Hospital||Temple, Texas 76508|